Cashu
Skye Bioscience Faces Class Action Lawsuits Over Alleged Drug Efficacy Misrepresentations
about 1 month ago
Stocks
Health Care
skye
Skye Bioscience
NASDAQ: SKYE
+0.02 (+2.60%)
0.755
USD
At close at Mar 04, 21:41 UTC
Overview
Loading chart...
Key Stats
Market Cap
22.80M
Dividend Yield
0.00%
P/E Ratio
-0.45
EPS
-0.73
Revenue
-
Avg. Volume
162.78K
About
What does SKYE do?
Skye Bioscience, a San Diego-based biopharmaceutical company, focuses on cannabinoid-based therapeutics for metabolic disorders and inflammation. Its Phase 2 candidates include nimacimab for obesity and SBI-100 OE for glaucoma.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.